Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Portable X-ray vision is one step closer to reality with OXOS Medical

From TechCrunch

By Haje Jan Kamps

April 5, 2023

Portable X-ray vision is one step closer to reality with OXOS Medical

The global medical imaging market was valued at a touch over $28 billion in 2021, and is only expected to rise with an increase in demand for early-detection services as well as lifestyle and age-related conditions. Yet at the same time as demand for radiology services is increasing, the number of available radiographers is decreasing. In the U.S., almost half of radiographers are approaching retirement age and there are fewer residents lining up to fill their soon-to-be vacancies. The situation in the U.K. is similarly critical, with a shortfall of 1,670 radiologists reported in the 2021 Royal College of Radiologists census, and no improvement in sight. It’s an area that’s not just ripe for improvement, but where the problem is urgent. It’s against that backdrop that OXOS Medical just raised $23 million in Series A funding with the intention of delivering a “radiology department in a box.”

“X-ray is the primary medical imaging modality, used at the beginning or end of over 70% of health interventions, but 80% of the world lacks access to imaging,” explains OXOS’ CEO and co-founder, Evan Ruff. Clearly, a lack of supply has the potential to negatively impact healthcare provision for millions of people, and OXOS believes it can help to alleviate that. “We aim to put safe, powerful and simple X-ray technology in the hands of urgent care centers, sports teams, home care and international mission operations, where a real-time diagnosis is critical to saving human lives.”

This $23 million Series A funding was from Parkway Venture Capital and Intel Capital, and brings OXOS Medical’s total funding to $45 million. It also saw Gregg Hill, Parkway Venture Capital co-founder and managing partner, and Eric King, Intel Capital investment director, join the OXOS board of directors to help accelerate the company’s growth. Ruff explained how this funding will be used to help scale up OXOS, as well as push on with its technological advantages.

Nanox, maker of a low-cost scanning service to replace X-rays, expands Series B to $51M

“This fundraise was all about setting OXOS up for scale,” says Ruff. “As a small company, there are certain things that we just can’t do. This money unlocks a number of new initiatives, everything from cost reduction activities, to product development, to advanced research, and other initiatives. Our goal is for anyone, anywhere, to be able to unpack an OXOS device and have a complete radiography solution available immediately.”

While OXOS is keen to continue to supply devices in traditional markets, it also recognizes that its technology is suited for use in a wide variety of medical and non-medical settings.

“OXOS devices use 80% less radiation than existing devices, shifting the envelope of what’s possible in radiography,” says Ruff. “OXOS’ smart and safe technology addresses the growing needs of orthopedic and radiographic professionals across all care scenarios, expanding access well beyond established sectors. We’re seeing massive pull into urgent care, professional sports and family practices, as well as other non-medical applications.”

OXOS claims that its devices are the only ones on the market that can provide both static images (digital radiography) and live imaging (dynamic digital radiography), for both diagnostic and surgical radiography, in any setting. Together with their low radiation profiles, and the ability to provide imaging from a small form factor, which is viewable by medical practitioners anywhere on any device via the OXOS Cloud Platform, OXOS believes it can make X-rays more accessible.

If the short-term goals focus on scaling, volume and pushing into other sectors, what about the long-term future for OXOS?

“Every year, the U.S. spends over $50 billion on radiography. There is another $75 to $100 billion spent worldwide. OXOS technology provides a safe, point-and-click, end-to-end solution for every one of those use cases,” says Ruff, showing how big a market is available to it, and how it’s possible to make a positive impact on healthcare. “As our volumes increase and the number of deployed OXOS devices increases, the OXOS platform will be a huge resource for researchers and diagnostic innovators to build on, automating radiographic diagnostics and making healthcare cheaper.”

“As we execute on our goals, OXOS will grow into an independent, public company,” says Ruff.

Portable X-ray vision is one step closer to reality with OXOS Medical by Haje Jan Kamps originally published on TechCrunch

Most Recent

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Neil Rimer thinks the AI money is coming back out

Neil Rimer thinks the AI money is coming back out

Neil Rimer, the venture capitalist who co-founded Index Ventures, predicts the historic wealth AI is generating in Silicon Valley will have to be redistributed, voluntarily or involuntarily.

Jul 17, 2026

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open-weight AI models for coding.

Jul 17, 2026

Similar Posts

Scan.com, which gives patients direct access to private medical imaging services, raises $12M

Scan.com, which gives patients direct access to private medical imaging services, raises $12M

Anyone in the U.K. who has tried to book an NHS medical appointment of late will know just how much of an ordeal it can be, with median waiting times for consultant-led elective care (i.e. pre-planned clinical treatment) currently sitting at around 14.6 weeks in England. This has led to a spike in people turning […]

Apr 16, 2023

Samsung may invest in $100M round for medical imaging startup Exo

Samsung may invest in $100M round for medical imaging startup Exo

Samsung's venture arm is looking to invest in California-based medical device startup Exo, Bloomberg reported.

May 27, 2025

Oxford spinout RADiCAIT uses AI to make diagnostic imaging more affordable and accessible — catch it at TechCrunch Disrupt 2025

Oxford spinout RADiCAIT uses AI to make diagnostic imaging more affordable and accessible — catch it at TechCrunch Disrupt 2025

“What we really do is we took the most constrained, complex, and costly medical imaging solution in radiology, and we supplanted it with what is the most accessible, simple and affordable, which is CT,” Sean Walsh, RADiCAIT’s CEO told TechCrunch.

Oct 27, 2025

Glass Health is building an AI for suggesting medical diagnoses

Glass Health is building an AI for suggesting medical diagnoses

While a medical student at UC San Francisco, Dereck Paul grew concerned that innovation in medical software was lagging behind other sectors, like finance and aerospace. He came to believe that patients are best served when doctors are equipped with software that reflects the cutting edge of tech, and dreamed of starting a company that’d […]

Sep 8, 2023

Most Recent

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Neil Rimer thinks the AI money is coming back out

Neil Rimer thinks the AI money is coming back out

Neil Rimer, the venture capitalist who co-founded Index Ventures, predicts the historic wealth AI is generating in Silicon Valley will have to be redistributed, voluntarily or involuntarily.

Jul 17, 2026

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open-weight AI models for coding.

Jul 17, 2026

Similar Posts

Scan.com, which gives patients direct access to private medical imaging services, raises $12M

Scan.com, which gives patients direct access to private medical imaging services, raises $12M

Anyone in the U.K. who has tried to book an NHS medical appointment of late will know just how much of an ordeal it can be, with median waiting times for consultant-led elective care (i.e. pre-planned clinical treatment) currently sitting at around 14.6 weeks in England. This has led to a spike in people turning […]

Apr 16, 2023

Samsung may invest in $100M round for medical imaging startup Exo

Samsung may invest in $100M round for medical imaging startup Exo

Samsung's venture arm is looking to invest in California-based medical device startup Exo, Bloomberg reported.

May 27, 2025

Oxford spinout RADiCAIT uses AI to make diagnostic imaging more affordable and accessible — catch it at TechCrunch Disrupt 2025

Oxford spinout RADiCAIT uses AI to make diagnostic imaging more affordable and accessible — catch it at TechCrunch Disrupt 2025

“What we really do is we took the most constrained, complex, and costly medical imaging solution in radiology, and we supplanted it with what is the most accessible, simple and affordable, which is CT,” Sean Walsh, RADiCAIT’s CEO told TechCrunch.

Oct 27, 2025

Glass Health is building an AI for suggesting medical diagnoses

Glass Health is building an AI for suggesting medical diagnoses

While a medical student at UC San Francisco, Dereck Paul grew concerned that innovation in medical software was lagging behind other sectors, like finance and aerospace. He came to believe that patients are best served when doctors are equipped with software that reflects the cutting edge of tech, and dreamed of starting a company that’d […]

Sep 8, 2023